A5000617220- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Radiopharmaceutical Chemistry and Applications
- Bone Tumor Diagnosis and Treatments
- Medical Imaging Techniques and Applications
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Oral and Maxillofacial Pathology
- Sarcoma Diagnosis and Treatment
- Management of metastatic bone disease
- Salivary Gland Tumors Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Boron Compounds in Chemistry
- Nonmelanoma Skin Cancer Studies
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Bone and Joint Diseases
- MRI in cancer diagnosis
- Radiation Dose and Imaging
- Cutaneous Melanoma Detection and Management
- Lung Cancer Treatments and Mutations
University of Campania "Luigi Vanvitelli"
2021-2024
Sapienza University of Rome
2024
National Center for Oncological Hadrontherapy
2018-2021
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2021
Ankara Yıldırım Beyazıt University
2019
Ospedale SS. Annunziata
2019
Ege University
2019
German Cancer Research Center
2017
Heidelberg University
2017
University of Naples Federico II
2017
The aim of this study is to evaluate results in terms local control (LC), overall survival (OS), and toxicity profile better identify factors influencing clinical outcome skull base chordoma treated with proton therapy (PT) carbon ion radiotherapy (CIRT).We prospectively collected analyzed data 135 patients between November 2011 December 2018. Total prescription dose the PT group (70 patients) CIRT (65 was 74 Gy relative biological effectiveness (RBE) delivered 37 fractions 70.4 Gy(RBE) 16...
Skull-base chordoma (SBC) can be treated with carbon ion radiotherapy (CIRT) to improve local control (LC). The study aimed explore the role of multi-parametric radiomic, dosiomic and clinical features as prognostic factors for LC in SBC patients undergoing CIRT. Before CIRT, 57 underwent MR CT imaging, from which tumour contours dose maps were obtained. MRI CT-based selected fed two survival models, singularly or by combining them factors. Adverse was given in-field recurrence progression....
Objective: To compare radiation-induced toxicity and dosimetry parameters in patients with locally advanced nasopharyngeal cancer (LANPC) treated a mixed-beam (MB) approach (IMRT followed by proton therapy boost) an historic cohort of full course IMRT-only.Material methods: Twenty-seven LANPC the MB were compared to similar 17 IMRT-only. The consisted first phase IMRT up 54–60 Gy second delivered boost 70–74 (RBE). total dose for IMRT-only was 69.96 Gy. Induction chemotherapy administrated...
Malignant melanoma of the lower genital tract is a rare disease known to have poor prognosis. Because high rate distant metastasis and unsatisfactory survival benefit, more conservative treatment approach, instead extensive surgery, may be warranted. Gynecological radioresistant tumor, an ideal test biological efficacy carbon ion radiotherapy (CIRT).To report our preliminary experience with CIRT in gynecological at National Center Oncological Hadrontherapy (CNAO).Between January 2016...
Background/Aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity critical organs, such as bowel. This study aimed at evaluating safety and efficacy re-irradiation with Carbon Ion Radiotherapy (CIRT) in patients local recurrence. Patients Methods: Between 2014 2018, 14 were treated National Center Oncological Hadrontherapy (CNAO Foundation) CIRT for cancer. Results: All concluded treatment. No G≥3 acute/late reaction nor pelvic infections observed. The...
Cemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to immunotherapy are still unknown. We collected data from locally advanced and/or metastatic cSSC patients treated with cemiplimab two Italian University centers. In addition, gene expression analysis by using Nanostring Technologies platform evaluate 770 cancer- immune-related genes on 20 tumor tissue samples (9 responders 11 non-responders...
Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available clinical practice. A novel easy-to-calculate marker is the quantitative analysis of calcium plaque coronary, calculated on CT. It called Agatston score (or CAD score). At same time, other potential predictors include ultrasonography anamnesis patients. Our work aimed to correlate with overall survival (OS) NSCLC We retrospectively analyzed...
The median overall survival (OS) and local control (LC) of patients with melanoma brain metastases (MBMs) are poor even immune checkpoint inhibitors and/or radiotherapy (RT). aims the study were to evaluate association timing stereotactic (SRT)/radiosurgery (SRS) performed CyberKnife® System ipilimumab (IPI). A total 63 MBMs analyzed: 53 received RT+IPI 10 RT alone. Therefore, divided into four groups: PRE-PI (>4 weeks before IPI) (18), CONC-IPI (4 before/between first last cycle/within 3...
Malignant peripheral nerve sheaths tumors (MPNST) are rare, highly aggressive and radioresistant of soft tissue. Carbon ion radiotherapy (CIRT) seems to be an attractive treatment option when surgery is not possible or refused by the patient. The aim this study was report our preliminary results (outcomes toxicity) CIRT in MPNSTs.Our retrospectively analyzed 13 patients (median age=54 years; range=23-72 years) with MPNST treated for a median total dose 73.6 Gy (relative biological...
Background: Liposarcomas are the most common soft-tissue sarcomas in adulthood. Orbital and spermatic cord liposarcomas uncommon there is no consensus on their management. The treatment of choice wide excision, which may be destructive lead to unacceptable morbidity. When surgery declined by patients recurrent disease, management can challenging. We report two cases liposarcoma treated with carbon ion radiotherapy at National Center for Oncological Hadrontherapy (Fondazione CNAO) Italy. Case...
Background/Objectives: Lutathera® ([177Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs). The bone marrow kidneys are critical organs RLT [177Lu]Lu-DOTA-TATE. Our purpose was to evaluate hematological renal toxicity in 29 (18 males, 11 females) treated Lutathera®. Methods: According standard protocols, four cycles...